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Abstract
Renal cell carcinoma (RCC) denotes cancer originated from renal epithelium and accounts for 
>90% of cancers in the kidney. The disease encompasses >10 histological and molecular subtypes, 
of which clear cell RCC (ccRCC) is most common and accounts for most cancer-related deaths. 
Although somatic VHL mutations have been described for some time, more-recent cancer 
genomic studies have identified mutations in epigenetics regulatory genes and demonstrated 
marked intratumour heterogeneity, which could have prognostic, predictive and therapeutic 
relevance. Localized RCC can be successfully managed with surgery whereas metastatic RCC is 
refractory to conventional chemotherapy. However, over the past decade, marked advances in 
treatment of metastatic RCC have been made, with targeted agents including sorafenib, sunitinib, 
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bevacizumab, pazopanib and axitini that inhibit vascular endothelial growth factor (VEGF) and its 
receptor(VEGFR) and everolimus and temsirolimus, which inhibit mTOR complex 1, being 
approved. Since 2015, agents with additional targets aside from VEGFR have been approved, such 
as cabozantinib and lenvatinib; immunotherapies such as nivolumab have also been added to the 
armamentarium for metastatic RCC. Here, we provide an overview of the molecular biology of 
RCC, with a focus on ccRCC, as well as updates to complement current clinical guidelines and an 
outline of potential future directions for RCC research and therapy.
INTRODUCTION
Renal cell carcinoma (RCC) encompasses a heterogeneous group of cancers derived from 
renal tubular epithelial cells1 and is among the 10 most common cancers worldwide. Key 
advances in histopathological and molecular characterization of RCC over the past two 
decades have led to major revisions in its classification2–5. Major subtypes6 with ≥5% 
incidence are clear cell RCC (ccRCC)7, papillary RCC (pRCC)8 and chromophobe RCC 
(chRCC)9 (FIG. 1). The remaining subtypes are very rare (each with ≤1% total incidence)5 
and in cases where a tumour does not fit any subtype diagnostic criteria, it is designated as 
unclassified RCC (uRCC, ~4% total incidence)10. ccRCC is the most common subtype and 
accounts for the majority of kidney cancer deaths and is the focus of this Primer11. Indeed, 
owing to the predominance of clear cell histology in metastatic disease (83–88%)12,13, 
tumours with non-clear cell histology have been grouped as ‘nccRCC’ (Table 1) for 
feasibility in conducting clinical trials14–16. Furthermore, recent cancer genomic studies 
have revealed an overt complexity of intra-tumour17–19 and inter-tumour7,20 heterogeneity in 
ccRCC, which could contribute to the heterogeneous clinical outcomes observed21–23.
Localized RCC can be treated with partial or radical nephrectomy (removal of the kidney)24, 
ablation25 (destruction of the malignant tissue with heat or cold) or active surveillance26 
(monitoring of tumour growth with periodic radiographic studies). Despite nephrectomy 
with curative intent, ~30% of patients with ccRCC with localized disease eventually develop 
metastases27–30, which require systemic therapies and is associated with high mortality. 
Targeted therapy against vascular endothelial growth factor (VEGF) and mTOR pathways 
have been developed, but treatment response is varied and most patients eventually 
progress31. However, increased genomic and molecular understanding of metastatic ccRCC 
has contributed to an unprecedented number of drugs approvals in the United States and 
European Union (currently 12 approved drugs with six different effective mechanisms of 
action are approved). In this Primer, we discuss these new approvals and the major progress 
made in biology of ccRCC that led to their development. Furthermore, we present insights 
into genomics-based risk and treatment stratification and discuss treatment sequencing and 
combinations that are paving the way for the future design of personalized clinical 
management plans.
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Kidney cancer accounts for approximately 2% of all cancer diagnoses and cancer deaths 
worldwide, with incidence rates generally higher in developed countries (FIG. 2)32. 
Annually, ~295,000 new kidney cancer cases are diagnosed and ~134,000 deaths are 
recorded worldwide33,34. Kidney cancer accounts for ~63,000 new cases and ~14,000 deaths 
yearly in the United States35, and for ~84,000 new cases and ~35,000 deaths in Europe36. 
Men are more affected than women (a 2:1 ratio of new diagnoses).
The median age of patients with RCC in the Surveillance, Epidemiology, and End Results 
(SEER) database in the United States was 64 years with a near normal distribution37. 
Accordingly, when RCC is diagnosed at younger ages (≤46 years, which represents the 
lowest decile of the age distribution)37,38, the possibility of an underlying hereditary kidney 
cancer syndrome — which accounts for 3–5% of all RCCs5 — should be considered (Table 
2)39,40.
The incidence of RCC highest in the Czech Republic, with age-standardized annual rates of 
22.1 and 9.9 new cases per 100,000 men and women, respectively, over the period 2003–
200741. The incidence is also very high in the Baltic and Eastern European countries, 
although the reasons for this excess are not known. Overall, incidence rates have been 
increasing over time in most populations, but mortality rates have levelled off or are 
decreasing since 1990s. This divergent pattern of increasing incidence and decreasing 
mortality is particularly evident in developed countries. For example, analyses within the 
SEER database indicate that the increase in RCC incidence is confined to small and 
localized tumours, likely due at least in part to increasingly frequent incidental detection of 
small renal masses (tumours ≤4 cm in size) that are unlikely to have metastasized from 
increased use of abdominal imaging42. The global increases in the prevalence of obesity, an 
established RCC risk factor, might also play a part in increasing incidence, as well as 
influencing clinical outcome41,43.
Risk factors
RCC incidence increases markedly with age and is higher for men than women. In the 
United States, incidence varies by ethnic group, with rates highest among Native American, 
Indigenous Alaskans and African Americans, and lowest among Asian Americans and 
people of Pacific Island descent35. The major established risk factors for RCC include 
excess body weight, hypertension and cigarette smoking44, which were factors in 
approximately half of all diagnosed cases in one US study45. Other medical conditions that 
have been associated with RCC in epidemiological studies include chronic kidney disease, 
haemodialysis, kidney transplantation, acquired kidney cystic disease, a previous RCC 
diagnosis and, possibly, diabetes mellitus44. Many lifestyle, dietary, occupational and 
environmental factors have also been associated with RCC with varying levels of 
evidence46.
For example, contradictory reports exist on the association between red meat consumption 
and RCC risk47,48. Moderate alcohol consumption (≥11g per day) seems to reduce the risk 
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for RCC48,49. In a case–control study on physical activity and the risk of RCC, inverse 
trends in risk were found, and the authors concluded that 9% of RCC cases could be avoided 
by increasing physical activity50. However, the inverse association might have involved other 
confounding factors such as BMI and social class correlates. Other studies have found no 
such inverse association51.
Genetic factors also contribute to RCC risk, as evidenced by individuals with a family 
history of renal cancer having an approximate twofold increased risk52. Investigations into 
familial RCC have uncovered mutations in at least 11 genes (namely BAP1, FLCN, FH, 
MET, PTEN, SDHB, SDHC, SDHD, TSC1, TSC2, and VHL), some of which have also 
been implicated in sporadic RCC development39. A notable example is VHL, the mutated 
gene underlying von Hippel-Lindau disease, which is characterized by a high risk of 
developing ccRCC53; inactivation of the VHL protein, leading to unchecked expression of 
oncogenic hypoxia-inducible factors (HIF-1 and HIF-2), is also a hallmark of sporadic 
ccRCC tumours (see Mechanisms, below)39,54. Genome-wide association studies (GWAS) 
of RCC have identified six susceptibility loci to date, on chromosome regions 2p21, 2q22.3, 
8q24.21, 11q13.3, 12p11.23 and 12q24.3155–58. The 2p21 locus maps to EPAS1, a gene 
encoding the HIF-2α subunit 55 whereas the biological effects underlying the 11q13.3 locus 
seems to be attributable to changes in the regulation of CCND1 (encoding cyclin D1, which 
is involved in cell cycle regulation)59. The locus 12p11.23 probably maps to changes in 
BHLHE41 (encoding basic helix-loop-helix family member e41, which is thought to have a 
role in regulation of the circadian rhythm)60. The disease genes underlying the other GWAS 
susceptibility loci have yet to be identified.
MECHANISMS/PATHOPHYSIOLOGY
Genes and pathways
In ccRCC, the VHL tumour suppressor gene is the most frequently mutated gene7,54, and its 
complete loss through genetic (point mutations, indels and 3p25 loss) and/or epigenetic 
(promoter methylation) mechanisms constitutes the earliest, truncal oncogenic driving 
event61,62. VHL is the substrate recognition component of an E3 ligase complex that 
ubiquitinates HIF-1α and HIF-2α for proteasome-mediated degradation53,63,64. Loss of 
VHL, therefore, leads to aberrant accumulation of HIF proteins despite an adequately 
oxygenated tissue microenvironment, which in turn results in uncontrolled activation of HIF 
target genes that regulate angiogenesis, glycolysis and apoptosis (FIG. 3). Accordingly, 
human ccRCC tumours are rich in lipids and glycogens, and are highly vascular65,66 — 
which underlies why agents that primarily inhibit VEGF and its receptor VEGFR are 
effective treatments for metastatic ccRCC14,15,67. However, VHL loss alone is insufficient to 
induce ccRCC as evidenced by the long latency (>30 years) in individuals who harbour 
VHL germline mutations to develop ccRCC53 and by the observation that Vhl loss in mice is 
unable to induce ccRCC68. These results suggest that additional genetic and/or epigenetic 
events are probably needed for ccRCC to develop69.
To identify these events, large-scale cancer genomic projects have been undertaken, and 
have revealed several novel prevalent mutations in ccRCC, including PBRM1 (29–41% of 
tumour samples), SETD2 (8–12%), BAP1 (6–10%), KDM5C (4–7%) and MTOR (5–
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6%)7,70–73. Interestingly, PBRM1, SETD2 and BAP1 encode chromatin and histone 
regulating proteins, are located at 3p21 and function as tumour suppressors7,70–72. As VHL 
resides at 3p25, a single copy loss of the short arm of chromosome 3 (3p) would result in 
haploinsufficiency of these four tumour suppressor genes, corroborating the fact that 3p loss 
(that is, loss of heterozygosity) is nearly a universal event in ccRCC61 and constitutes an 
early genetic event69. By contrast, MTOR mutations in ccRCC are generally missense and 
functionally activating73,74, which could explain the reason mTOR pathway inhibitors, 
including everolimus and temsirolimus, are effective75,76.
How individual mutations and their interactions contribute to the pathogenesis and their 
values as prognostic or predictive biomarkers in ccRCC are largely unknown. Nevertheless, 
a few studies have demonstrated interesting clinical correlations that warrant future 
validation. As inactivation of VHL is the founding event of ccRCC, its mutation status has 
no effect on clinical outcome, whereas mutations involved in disease progression such as 
PBRM1, SETD2 and BAP1 as well as KDM5C (which is also involved in chromatin 
modification) were shown to associate with aggressive clinical features77–79. Small renal 
masses harbouring PBRM1 mutations were associated with stage III pathological features 
(that is, extrarenal growth but not extending beyond Gerota’s fascia see below)71, whereas 
BAP1 mutations were associated with larger tumour sizes, higher Fuhrman nuclear grade 
(large nucleus with prominent nucleolus) and worse cancer-specific survival77,78,80. 
Interestingly, mutations in BAP1 and PBRM170 or KDM5C20 seem to occur mutually 
exclusively in ccRCC, offering a molecular subclassification of ccRCC. Furthermore, 
mutations of KDM5C, which is located at Xp.11, were predominantly detected in male 
patients and correlated with long-term therapeutic benefit from sunitinib20; and mutations of 
SETD2 were associated with reduced relapse-free survival80.
Tumour heterogeneity and cancer evolution
As Nowell first described 40 years ago81, genetic diversity within tumours is thought to 
provide the substrate upon which selection can act, to enable tumours to adapt to new 
microenvironmental pressures and metabolic demands during the natural history of the 
cancer (FIG. 4A). Such genetic diversity has been studied extensively in ccRCC. For 
example, in a study of four patients with ccRCC who had multiple tumours were subjected 
to multi-region genetic analysis, VHL mutation and 3p loss of heterozygosity were found to 
be ubiquitous events across all regions sampled17. By contrast, common driver events such 
as SETD2, PBRM1, MTOR, PIK3CA, PTEN and KDM5C mutations were present 
heterogeneously within the primary tumour and metastatic sites — in some regions but not 
others. Such genetic characteristics enable the construction of tumour phylogenies, whereby 
the ‘trunk’ of the evolutionary tree depicts mutations found in the most recent common 
ancestor (MRCA) that are present in every tumour cell. ‘Branched’ mutations are found in 
some subclones but not others; these mutations may be regionally distributed across the 
tumour, occupying distinct regional niches within the primary tumour or different niches 
between the primary and metastatic sites of disease.
Furthermore, parallel evolution has also been observed, whereby recurrent branch alterations 
in subclones affect the same gene, signal transduction pathway or protein complex (FIG. 
Hsieh et al. Page 5





















4B). In some cases — such as BAP1, PBRM1 and SETD2 mutations — such recurrent but 
distinct alterations can be readily explained as the ‘second hit’ event in the evolution of the 
tumour. In other cases, parallel evolution suggests considerable selection pressures for 
disruption of the same signalling pathway or protein complex. Additionally, convergence of 
genetic characteristics has been noted in several studies of ccRCC19,23,82, whereby 
mutations in genes occur at different time points but result in similar overall genomic and 
phenotypic profiles; a ‘braided river’ model has been conceived to illustrate this 
phenomenon (FIG. 4C)69. Regardless of the modality, a follow up study of ccRCC samples 
for eight patients demonstrated evidence for branched evolution in which 73–75% of driver 
alterations were found to be subclonal18.
Multi-region tumour analyses suggest the intriguing possibility that evolutionary trajectories 
are remarkably constrained in ccRCC, which — as our knowledge of microenvironmental, 
therapeutic and host selection pressures grows — could render the evolutionary routes 
predictable and, therefore, therapeutically tractable. For example, it has been shown that 
patients who responded well to mTOR inhibition harbour recurrent regionally separated 
aberrations in components of the mTOR pathway75. Furthermore, some subclonal alterations 
might be involved in the initiation and maintenance of cell-to-cell variation necessary for 
clonal selection. For example, SETD2 loss of function has been shown to impair nucleosome 
compaction, minichromosome maintenance complex component 7 (MCM7) function and 
DNA polymerase delta loading to chromatin, resulting in impaired DNA replication fork 
progression. Additionally, failure to load lens epithelium-derived growth factor p75 splice 
variant (LEDGF) and DNA repair protein RAD51 homolog 1 (RAD51) — which are 
involved in DNA break repair — has also been observed upon SETD2 loss, resulting in 
homologous recombination repair deficiency83. These events are, accordingly, plausible 
genomic biomarkers in ccRCC dispersed within distinct regional niches within each 
tumour19,84.
Immune infiltration and the tumour microenvironment
In addition to genetic alterations, gene expression, metabolic and immunological analyses of 
ccRCC have also yielded important mechanistic and clinical insights 20,85–87. Of these, 
perhaps the immune infiltration characteristics of ccRCC is of increasing interest, given the 
rise of immune checkpoint-blocking therapies in this disease (see below, Management). 
Notably, among 19 cancer types examined by The Cancer Genome Atlas research 
programme, ccRCC has the highest T cell infiltration score 87. Furthermore, higher nuclear 
grade and stage in ccRCC was correlated with an increase in T helper 2 and T regulatory cell 
infiltration87,88.
Disease models
Although RCC cell lines have been used for mechanistic studies, 89 ccRCC tumours in 
patients are highly vascular — a feature that cannot be recapitulated with in vitro cell 
studies. Furthermore, such cell lines can acquire additional genetic and/or epigenetic 
changes during passages such that in vitro drug screens do not yield specific, translatable 
insights90. Nevertheless, when these cell lines were injected subcutaneously into laboratory 
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animals, xenografted tumours largely respond to anti-VEGF therapy91 and can be used to 
investigate resistance mechanisms92,93.
More recently, patient-derived xenograft (PDX) models have been established and have been 
shown to recapitulate the patient’s documented clinical response to targeted therapies, which 
could be used in pre-clinical drug trials94. At the same time, efforts to develop mouse 
models that truly reflect human ccRCC genomics and morphology have been hampered by 
the fact that homozygous inactivation of the Vhl gene in mice does not result in ccRCC68. 
However, the identification of additional recurrent, prevalent mutations in human ccRCC 
have rekindled efforts to generate such models. For example, homozygous deletion of Vhl 
and Pbrm1 in a mouse model resulted in multifocal, lipid-rich, glycogen-rich, transplantable 
ccRCC (J.J.H., unpublished data). Interestingly, homozygous deletion of Vhl and Bap1 in a 
mouse model resulted in early lethality (<1 month), and some mice (within a cohort of 7) 
carrying homozygous deletion of Vhl and heterozygous deletion of Bap1 developed tumour 
micronodules (0.25–1.8mm) with unknown tumour incidence and molecular characteristics 
95
. Overall, animal models of RCC are currently limited but being eagerly pursued.
DIAGNOSIS, SCREENING AND PREVENTION
Diagnosis
Historically, patients were diagnosed with RCC after presenting with flank pain, gross 
haematuria and a palpable abdominal mass. Nowadays, the majority of diagnoses result from 
incidental findings. This shift is a consequence of the widespread use of non-invasive 
radiological techniques such as ultrasonography or abdominal CT imaging performed for 
another reason. That being said, paraneoplasic syndromes — symptoms caused by hormones 
or cytokines excreted by tumour cells or by an immune response against the tumour — are 
not uncommon in RCC 96 and symptoms include hypercalcaemia, fever and erythrocytosis. 
Most of these symptoms are usually reversed after tumour resection11. Diagnosis is usually 
strongly suspected by imaging studies although RCCs can display variable radiographic 
appearances97. Typical radiological features for ccRCC include exophytic (outward) growth, 
heterogeneity due to intratumoral necrosis or haemorrhage and high uptake of contrast-
enhancement agents98.
Staging
The stage of RCC reflects the tumour size, extent of invasion outside of the kidney, the 
involvement of lymph nodes and whether the tumour has metastasized (FIG. 5). CT imaging 
with contrast enhancement of the chest, abdominal cavity and pelvis is required for optimal 
staging. Such imaging enables assessment of primary tumour (size and whether the tumour 
is organ-confined or extends to perinephric fat or kidney hilum), regional spread (lymph 
node involvement) and distant metastases (lung, bone and distant lymph nodes). MRI can 
also provide additional information, especially to determine whether the tumour extends into 
the vasculature (vena cava tumour thrombus). Bone scan, 18F-fluorodeoxyglucose PET and 
imaging of the brain are not systematically recommended for initial staging14,15. Prognostic 
assessment will require further laboratory testing that includes, but is not limited to, 
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haemoglobin, leukocyte and platelet counts; serum-corrected calcium levels; and lactate 
dehydrogenase levels99,100.
Genomic implications
An age of onset of ≤46 years raises the possibility of a hereditary syndrome (Table 2) and, 
according to the American Society of Clinical Oncology, should trigger consideration for 
genetic counselling and might serve as a useful cut-off age when establishing genetic testing 
guidelines37. Indeed, awareness of the non-renal malignancies and non-neoplastic features 
associated with RCC is of interest to the physician to identify hereditary syndromes40. 
Furthermore, specific therapeutic options driven by the underlying biology are now being 
developed for these different RCC related to cancer susceptibility syndromes101. Upon 
confirmation, patients and their families harbouring mutations are subject to specialized 
monitoring and treatment plans to minimize morbidity and prevent mortality.
Histopathological confirmation
Histopathological confirmation of malignancy is obtained either with renal core biopsy or on 
the partial or radical nephrectomy specimen. Initial biopsy is recommended before ablative 
therapy is undertaken (in those for whom surgery is not an option) or before initiating 
systemic therapy (in those who have metastatic disease)102. In 2016, the WHO classification 
of RCC was updated5 from previous (2004) WHO1 and International Society of Urological 
Pathology (ISUP) Consensus Conference4 (2013) systems. Although most RCCs can be 
easily classified on the basis of histological criteria, some tumours pose a diagnostic 
problem because they display a combination of features characteristic of different subtypes. 
For instance, the presence of clear cells is not unique to ccRCC but can be observed in 
pRCC, chRCC and MiT family translocation RCC (tRCC)66. Similarly, papillary structures, 
characteristic of pRCC, can be present in other RCC types103. In challenging cases, careful 
evaluation of cytological features, growth pattern, immunophenotype and genetic alterations 
usually enables the proper diagnosis. However, a subset of RCCs (~4%) cannot be assigned 
to any specific category because they either present combined morphologies or display 
unusual features and are, therefore, designated uRCC3,104,105. Nevertheless, a recent 
molecular characterization of 62 aggressive uRCC revealed distinct subsets including NF2 
loss (26%), mTORC1 pathway activation (21%) and mutations in chromatin and DNA 
damage regulators (21%)10.
At macroscopic examination, the cut surface of the ccRCC tumours is golden yellow with 
frequent haemorrhagic, necrotic and cystic areas. Microscopically, ccRCC usually consists 
of tumour cells with clear cytoplasm arranged in nests or tubules surrounded by a rich 
vascular network. The clear appearance of the cytoplasm is due to the accumulation of 
glycogen and lipids. A variable proportion of tumour cells with granular eosinophilic 
cytoplasm can be observed and, in some cases, these cells constitute the entire tumour 
mass3,104,105. The most widely used grading system for ccRCC is the Fuhrman grading 
system, which defines four nuclear grades (1–4) in order of increasing nuclear size, 
irregularity and nucleolar prominence106. The Fuhrman nuclear grade has been shown to 
have prognostic value in ccRCC30,107,108.
Hsieh et al. Page 8





















It should be noted that all RCC types can contain foci of high-grade malignant spindle cells 
(that is, sarcomatoid differentiation). Thus, sarcomatoid RCC is no longer considered as an 
entity but rather as a progression of any RCC type109. Of note, recent genomic insights from 
sequencing matched sarcomatous and carcinomatous RCC demonstrated enrichment in 
TP53 and CDKN2A mutations, implicating these genetic defects as underlying causes of 
sarcomatoid differentiation in RCC110–112.
Screening
Owing to the relatively low incidence of RCC, universal screening (such as that for 
asymptomatic micro-hematuria) has not demonstrated a positive effect on outcomes in 
RCC113. Furthermore, other biomarkers have not yet been established for screening114,115. 
Imaging remains the primary tool for RCC detection and screening. An ultrasonography 
screening study in 45,905 participants reported a 10-fold higher RCC-incidence than 
expected for a general population with improved cancer-free survival when compared with 
symptomatic patients116.
Although most cases are sporadic62, the majority of patients with RCC might have a genetic 
predisposition38,117. Although, no guideline is available regarding the selection of patients 
for germline mutation testing, guidelines for monitoring those with confirmed hereditary 
syndromes that increase the risk of RCC are available37.
Prevention: modifiable risk factors
Smoking, obesity and hypertension are associated with increased risks of developing RCC 
whereas exercise and moderate consumption of alcohol and flavonoids reduce RCC risks.
Tobacco—When compared to never smokers, a relative risk for ever smokers of 1.38 
(95%CI=1.27–1.50) was reported in a meta-analysis including 8,032 cases and 13,800 
controls from 5 cohort studies118. A dose-dependent increase in risk in both men and women 
was found; individuals who had quit smoking >10 years prior had a lower risk when 
compared to those who had quit <10 years prior. Other studies have confirmed smoking as a 
risk factor for RCC119.
Obesity—A 5 kg/m2 increase in body mass index (BMI) was found to be strongly 
associated with RCC120. Similarly, a strong association between weight gain in early and 
mid-adulthood (18–35 years of age) with RCC was reported121. Moreover, central adiposity 
(relative risk 1.8, 95%CI 1.2–2.5) and the waist-to-hip ratio (0.86–2.88) was positively 
associated with RCC in women122. The impact of BMI on overall survival was also studied 
in 1,975 patients treated with targeted agents. The authors reported on a median overall 
survival of 25.6 months (95%CI 23.2–28.6) in patients with high BMI versus 17.1 months 
(95%CI 15.5–18.5) in patients with low BMI (adjusted hazard ratio of 0.84, 95%CI 0.73–
0.95)123. Compared with stable weight, neither steady gain in weight nor weight loss was 
significantly associated with risk of RCC121.
Hypertension and medications—Higher BMI and hypertension were independently 
shown to increase the long-term risk of RCC in men whereas a reduction in blood pressure 
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lowered the risk124. Aspirin use was found to be associated with an increased RCC risk in 
one out of five studies125; by contrast, paracetamol (acetaminophen) exposure showed no 
increased risk126. The role of phenacetin (acetophenetidin) exposure has been 
inconclusive127. Statins were reported to significantly reduce the risk of RCC in a large 
analysis (n=483,733), with a 48% risk reduction (adjusted odds ratio 0.52, 95%CI 0.45–
0.60)128. However, owing to the sporadic and low frequency nature, current guideline does 
not support the role of empiric treatment for prevention of RCC in general population; 
patients with hereditary syndromes should be monitored more closely and treated 
accordingly.
MANAGEMENT
For patients with surgically resectable RCC, the standard of care is surgical excision by 
either partial or radical nephrectomy with a curative intent. By contrast, those with 
inoperable or metastatic RCC typically undergo systemic treatment with targeted agents 
and/or immune checkpoint inhibitors. Deciding on which treatment has been largely guided 
by various nomograms30. For example, the UCLA Integrated Staging System (UISS) and 
Stage Size Grade and Necrosis (SSIGN) score integrate clinical (1997 TNM stage) and 
pathological (Fuhrman nuclear grade) information to recommend the length and frequency 
of clinical follow-up and the selection of high-risk patients for adjuvant studies129–131. 
Similarly, key prognostic factors have been identified, validated and adopted to guide and 
stratify patients with metastatic RCC for systemic treatment, including performance status, 
time from diagnosis to systemic treatment and blood levels of haemoglobin, neutrophils, 
platelets, calcium and lactate dehydrogenase99,132,133.
Surgery
Surgical treatment of RCC is related to the clinical stage of the disease and to the general 
condition of the patient (FIG. 5). Although typically reserved for localized disease, both 
partial and radical nephrectomy can also be used with cytoreductive intent in patients with 
metastatic disease. Indeed, randomized controlled trials (RCTs) demonstrating the benefit of 
this approach date from the 1990s, when cytokine-based therapies dominated the systemic 
therapy landscape. Furthermore, although most patients included in RCTs of targeted 
therapies also underwent cytoreductive nephrectomy, the current role of excision of the 
primary tumour in these patients has yet validated. However, according to main international 
guidelines many centres in offer cytoreductive nephrectomy if there is a substantial disease 
volume at the primary site but only a low burden of metastatic disease134
Partial nephrectomy—The goal of partial nephrectomy is to completely remove the 
primary tumour while preserving the largest possible amount of healthy renal parenchyma. 
Partial nephrectomy is indicated for patient with T1 tumours (according to the Union for 
International Cancer Control TNM staging system) and a normal contralateral kidney 
(elective indication). Moreover, partial nephrectomy is strongly recommended (imperative 
absolute indications) in patients with RCC who have only one kidney (anatomically or 
functionally), in those with bilateral synchronous RCC and in those with von Hippel-Lindau 
syndrome. Similarly, imperative relative indications include conditions that can impair renal 
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function (for example, kidney stones, hypertension, diabetes and pyelonephritis). Indeed, 
partial nephrectomy offers lower renal function impairment135–137 and equivalent 
oncological survival outcomes compared with radical nephrectomy in those with T1 
tumours138,139. More controversial is the favourable impact of partial nephrectomy on 
overall survival140,141 because conventional wisdom dictates that removal of the whole 
kidney is better in terms of oncological outcome. In this scenario, surgical feasibility 
remains the main factor influencing the final decision making process.
In the past decade, nephrometry scoring systems have been proposed to predict the 
complexity of the partial nephrectomy procedure and predict perioperative outcomes 
according to the anatomical and topographical tumour characteristics (Table 3)142. The 
R.E.N.A.L. and PADUA nephrometry systems are still the most popular and most used tools 
to preoperatively classify tumours 143. These first-generation systems, along with the 
Centrality Index system, mainly factor in tumour-related anatomical parameters, including 
face location (that is, anterior or posterior faces, accordingly to their coverage by the anterior 
or posterior layers of the renal fascia, respectively), longitudinal polar location, rim location 
(that is, whether the tumour is located at the lateral or medial rim of the kidney), degree of 
tumour extension into the parenchyma, renal sinus involvement, upper urinary collecting 
system involvement and clinical maximal diameter of the tumour. Clinical studies 
demonstrated that such nephrometry systems were able to predict the risk of bleeding and 
post-operative complications in patients who underwent partial nephrectomy 142. Thus, they 
represent valid tools for counselling patients and selecting the ideal candidate for partial 
nephrectomy according to surgeon experience 143. Second-generation nephrometry systems, 
such as Diameter-Axial-Polar system, Zonal NePhRo scoring system and Arterial Based 
Complexity System, should be externally validated and tested head-to-head against a first-
generation system before being introduced in the clinical practice.
Laparoscopic partial nephrectomy (LPN) and robot-assisted partial nephrectomy (RAPN) 
are the main alternative to classical open partial nephrectomy (OPN). However, RAPN and 
OPN are more appropriate in the treatment of more-complex cases (based on expert 
opinion). Conversely, LPN should be reserved for small tumours (usually ≤4 cm in size) in 
patients without complex features as defined according to nephrometry systems (low- or 
intermediate-risk categories). Available meta-analyses have demonstrated that RAPN 
provides equivalent perioperative outcomes to LPN, but a significantly shorter warm 
ischaemia time144,145. Moreover, RAPN seems to be significantly better than OPN in terms 
of perioperative complications, estimated blood loss and hospital stay146,147. Conversely, 
transfusion rate, ischaemia time, estimated glomerular filtration rate change and early cancer 
outcomes are similar between the two approaches147. International guidelines recommended 
the use of both approaches according to the surgeon and patient preferences.
Finally, partial nephrectomy can also involve simple enucleation — entirely sparing the 
healthy parenchyma around the tumour. Alternatively, classic enucleoresection whereby a 
thin layer of healthy parenchyma is removed or polar or wedge resection whereby a wider 
excision of healthy parenchyma is performed are also viable options. A minimal tumour-free 
surgical margin following partial nephrectomy seems appropriate to avoid the increased risk 
of local recurrence24. Positive surgical margins have been reported in 1–6% of cases 
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regardless the type of used surgical technique148. Haematuria, perirenal haematoma and 
urinary fistulas are the most common complications of partial nephrectomy procedures. Less 
frequent postoperative complications can be represented by acute renal impairment and 
infection149.
Radical nephrectomy—Classical radical nephrectomy consists in the removal of kidney, 
perirenal fat tissue, adrenal gland and regional lymph nodes. However, in patients with 
tumour ≤5 cm in size, located at the inferior pole, the adrenal gland can be spared. Similarly, 
regional lymph nodes dissection can be reserved for patients with clinically positive nodes 
detected by CT or during the surgical procedure 150. Radical nephrectomy can be considered 
in cases with multiple small renal tumours, in cases in which the tumour extends into the 
vasculature and can be a laparoscopic or open procedure (FIG. 6). In most patients with 
stage I and II tumours, radical nephrectomy is currently performed using a traditional 
laparoscopic approach; the open approach remains the gold standard for the treatment of 
more complex cases. In experienced hands, the robot-assisted approach can represent a 
potential alternative to open surgery in cases with venous tumour thrombus.
Data recently extracted from the US National Cancer Data Base support the use of 
cytoreductive nephrectomy in those with metastatic disease even while they receive systemic 
targeted therapies. Indeed, the median overall survival was 17.1 months in cytoreductive 
nephrectomy cases versus 7.7 months in non-cytoreductive nephrectomy group151.
Active surveillance and ablative therapies
Active surveillance and ablative techniques such as cryotherapy or radiofrequency ablation 
are alternative strategies for elderly patients and/or those with competing health risks and 
limited life expectancy that renders them unsuitable for surgery15,24.
A definite protocol for active surveillance has yet to be defined. The most common approach 
consists of alternating between ultrasonography imaging and CT or MRI every 3 months in 
the first year, every 6 months in the second year and annually thereafter. Intervention should 
be considered for growth to >3–4 cm or by >0.4–0.5 cm per year152. Data from the Delayed 
Intervention and Surveillance for Small Renal Masses (DISSRM) registry in the United 
States showed that in a well-selected cohort of patients with up to 5 years of prospective 
follow-up, active surveillance was not inferior to primary intervention in terms of both 
overall survival and cancer-specific survival 26.
Ablative technology must be able to completely destroy all viable tumour tissue with no area 
of viable tumour left. Both cryotherapy and radiofrequency ablation can be performed using 
a laparoscopic or percutaneous approach under a CT or ultrasound guidance. A meta-
analysis of case series showed 89% and 90% of efficacy for cryoablation and radiofrequency 
ablation, respectively25; complication rates are 20% and 19%. Available low quality studies 
suggest a higher local recurrence rate for ablative therapies compared with partial 
nephrectomy153.
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The past 10 years have seen the approval of a number of targeted therapeutic agents and one 
immunotherapy agent for the treatment of metastatic RCC (FIG. 7). However, in the 
adjuvant setting after surgery, the situation is less clear and a randomised trial (ASSURE) of 
sunitinib versus sorafenib versus placebo showed no benefit for either drug therapy in terms 
of disease-free survival131. Notably, a recent study in the adjuvant setting reported a disease-
free survival benefit for 1 year of sunitinib therapy in comparison with observation in the S-
TRAC trial130. A number of other trials of adjuvant targeted therapies (such as PROTECT 
and SORCE) have completed accrual and will report outcomes in the next 12 months.
Targeted therapies—Given the highly vascular nature of RCCs, it is unsurprising that 
several therapies are available to exploit this feature. Indeed, tyrosine kinase inhibitors 
targeting the VEGF signalling axis approved in the first-line and second-line settings for the 
treatment of metastatic RCC in United States and European Union are sorafenib, sunitinib, 
pazopanib, axitinib, lenvatinib and cabozantinib154–159. All approvals have been as single 
agents except the combinations of lenvatinib with everolimus; additionally, the anti-VEGF 
monoclonal antibody bevacizumab is approved for use with interferon-α160,161. Broadly 
speaking, sunitinib, pazopanib and the combination of bevacizumab and interferon-α are 
approved as first-line options whereas axitinib and cabozantinib are approved in the second 
line. The mTOR inhibitors everolimus and temsirolimus are approved as single agents in the 
second-line setting and in the first line in patients with poor risk status162,163. Indeed, 
arguably the landmark trial of first-line systemic therapy of metastatic RCC was the phase 3 
study of sunitinib versus interferon-α reported in 2007 in which the superiority of sunitinib 
in terms of response rate, progression free and overall survival was reported155. This trial 
established sunitinib as the standard of care and the drug remains the comparator for all 
currently recruiting phase 3 studies of new drugs.
No clinically usable markers are available to select patients for particular therapies, despite 
intensive efforts. As such, the average duration of disease control with these drugs is 8–9 
months in the first line setting and 5–6 months in the second line setting. Most of the phase 3 
RCTs leading to the approval of these agents have excluded patients with nccRCC (Box 1) 
and as such this evidence base relates largely to ccRCC. Furthermore all of these agents are 
given continuously until disease progression in the absence of major toxicity. Furthermore, 
alternative schedules such as those electively interrupting therapy for prolonged periods have 
not been reported from RCTs.
Box 1
Limitations in the management of nccRCC
From the perspective of surgical management, the presence of non-clear cell histology 
rarely has a bearing on treatment and, in fact, histological subtype is often unknown pre-
operatively. Limited data are available to guide medical management of non-clear cell 
renal cell carcinoma (nccRCC) as a consequence of the exclusion in general of non-clear 
cell histologies from registration trials of targeted agents over the past 10 years. 
Importantly, the tumours classed as nccRCC are fundamentally different; there is no 
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reason to suppose that a therapy effective for papillary RCC would be effective for 
chromophobe or indeed any other subtype of kidney cancer. Nevertheless, some trials 
have been carried out and have broadly established sunitinib as a reasonable first line 
option in nccRCC, although the efficacy is less than for clear cell renal carcinoma 
(ccRCC). Most patients with metastatic nccRCC are treated with targeted agents 
approved for ccRCC, with the data favouring VEGF inhibitors over mTORC1 
inhibitors204,22,205. Unfortunately, most patients with nccRCC succumb to their diseases 
within 18 months despite systemic treatment12,13,204,205,206, and currently there is no 
evidence base for the treatment of nccRCC with checkpoint inhibitors. Encouragingly, a 
recent phase 2 trial reported everolimus plus bevacizumab as an effective combination in 
treating nccRCC in patients whose tumours display papillary features, achieving an 
overall response rate at 43% and a median progression free survival at 12.9 months194. 
Arguably, everolimus plus bevacizumab should be considered as the comparison arm in 
trials in rare RCC subtypes displaying predominant papillary morphology (papillary RCC 
type I and type II, and unclassified RCC with papillary features). Overall, the advances 
made are encouraging, but drug therapies tailored specifically to subtype remains an 
unmet need. Initiatives such as rarekidneycancer.org set up by experts and patient 
advocates are important steps to encourage rapid communication among patients with 
rare kidney cancer, doctors specialized in nccRCC and trialists.
Immunotherapy—Cytokines such as interferon-α and high dose IL-2 that enhance anti-
tumour immune activity have been used since the 1990s to treat metastatic RCC and were 
standards of care prior to the introduction of sunitinib164. Both drugs typically benefit only a 
small subset of patients (generally those with intrinsically favourable disease biology) and 
are associated with significant toxicity, particularly in the case of high-dose IL-2. Many 
studies are currently investigating combinations of anti-VEGF therapy with new-generation 
of immunotherapy agents in the form of T-cell immune checkpoint inhibitors such as the 
antibodies against programmed cell death protein 1 ligand 1 (PDL1), which include 
avelumab and atezolizumab, and antibodies against programmed cell death protein 1 (PD1), 
which include nivolumab and pembrolizumab). PD1 negatively regulates T cell function and 
its ligand PDL1 is highly expressed by cancer cells; accordingly, blockade of the PD1–PDL1 
axis promotes T cell activation and immune killing of the cancer. Another combination 
under investigation (Checkmate 214, NCT02231749) is nivolumab with ipilimumab, an 
inhibitor of the T-cell checkpoint cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). 
CTLA-4 also downregulates T cell function; its inhibition by these antibodies promotes T 
cell activation.
Nivolumab was approved in United States and European Union after the Checkmate 025 
RCT showed an overall survival benefit compared with everolimus in patients who had 
failed prior therapy with sunitinib and pazopanib165. However, the response rate to 
nivolumab was only 25% (5% for everolimus) and most patients treated did not experience 
significant tumour shrinkage. Although these check point inhibitors show promise, 
predicting response is difficult. In Checkmate 025, for example, PDL1 expression did not 
correlate with response, as had been reported in other trials in other cancer types 165. The 
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reason for this observation is unknown, but PD-L1 expression is dynamic in space and time 
and archival (paraffin-embedded) material from the primary tumour used in Checkmate 025 
might not have been representative of PD-L1 expression at metastatic tumour sites.
Finally, nivolumab is well tolerated compared with everolimus. Furthermore, it has been 
possible to combine nivolumab (and other anti-PD1 or anti-PDL1 therapies) with ‘clean’ 
(that is, more-specific, less-toxic and easier to combine) anti-VEGF therapies such as 
axitinib and bevacizumab, leading to a number of phase 3 studies of such combinations in 
metastatic RCC.
QUALITY OF LIFE
Quality of life and patient reported outcomes have become an important way to assess 
therapeutic strategies in the treatment of patients with RCC. Adverse events are important to 
consider and these are summarized in Table 4. Although oncological outcomes such as 
survival are more objective, validated quality of life measures have been developed to help 
assess the patient experience.
For localized RCC, a systematic review was performed which included data from 29 studies 
that included randomized and non-randomized studies149. It noted that quality of life 
outcomes after partial nephrectomy were superior to those of radical nephrectomy regardless 
of approach or technique. Interestingly, no good evidence suggested that cryotherapy or 
radiofrequency ablation had better quality of life outcomes compared to nephrectomy.
For metastatic RCC, quality of life measures become more important as treatment is usually 
palliative and patients continually balance quality versus quantity of life. A validated 15-
question tool called the Functional Assessment of Cancer Therapy (FACT)–Kidney Cancer 
Symptom Index (FKSI) is the most specific to kidney cancer 166. A subscale of this, the 
FKSI-DRS (disease-related symptoms) has nine kidney cancer-specific questions on the 
topics of lack of energy, pain, weight loss, bone pain, fatigue, shortness of breath, cough, 
fever and haematuria. Other more-general questionnaires exist and have been used in RCC 
clinical trials, including the Functional Assessment of Cancer Therapy General (FACT-G), 
the EuroQOL EQ-5D and Visual Analogue Scale (VAS)167. These tools enable investigators 
to assess quality of life; however, limitations including questionnaire burden, incomplete 
answering and defining a truly clinically significant minimal difference in quality of life 
scores remain.
In the phase 3 registration trial of first-line sunitinib versus interferon-α in the metastatic 
setting, the FKSI, FKSI-DRS, FACT-G, EQ-5D and EQ-VAS demonstrated a consistent 
favourable difference in quality of life for sunitinib 155. This finding can probably be 
attributed to the favourable adverse effect profile of sunitinib, which is associated with less 
fatigue than interferon-α, and higher efficacy of sunitinib (31% response rate) compared 
with interferon-α (6%).
Quality of life was assessed with FKSI-19, the Functional Assessment of Chronic Illness 
Therapy-Fatigue (FACIT-F), Cancer Therapy Satisfaction Questionnaire (CTSQ) and Seville 
Quality of Life Questionnaire (SQLQ) in the COMPARZ clinical trial comparing first line 
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sunitinib versus pazopanib156. Measurements were taken at baseline and at day 28 of each 
treatment cycle, which is typically the point of highest sunitinib toxicity (including soreness 
in mouth, throat, hands and feet). Improved quality of life scores were observed in those 
patients taking pazopanib versus those taking sunitinib.
The immune checkpoint inhibitors have also had quality of life analyses reported167. In the 
Checkmate 025 study of nivolumab used the FKSI-DRS score, these were performed at 
baseline and every 4 weeks up to study week 104 after which assessments were reduced. 
Median time to health-related quality of life improvement was shorter in patients given 
nivolumab (4.7 months, 95% CI 3.7–7.5) than in patients given everolimus (median not 
reached). The overall survival of patients was longer in those who had high baseline health-
related quality of life scores who then improved than those with similar baseline whose 
scores then deteriorated. The shortest overall survival was observed in those with low 
baseline scores who then deteriorated.
OUTLOOK
With the considerable advances in the molecular biology and management of RCC over the 
past several decades, it is not without reason that one could describe the current era of 
knowledge and available treatments as the ‘golden age’ of research. If we are to progress 
further, advances in diagnosis, local management and systemic therapy are needed to 
achieve >80% long-term survival that might define the future ‘diamond age’ of kidney 
cancer research and therapy (FIG. 7). Areas that currently show promise include developing 
strategies for treating high-risk patients, biomarkers to guide treatment and preventing and 
overcoming drug resistance.
Biomarkers to guide treatment
Although wide ranging clinical outcomes can be attributed to tumour heterogeneity in RCC, 
opportunities to further improve clinical outcomes on the basis of individual tumour 
characteristics (so called precision medicine) is an emerging field. Given that nivolumab, 
cabozantinib and lenvatinib were only recently approved, and few correlative studies have 
been reported, potential biomarkers for VEGF and mTOR inhibitors currently have the most 
promise.
Biomarkers can range from clinical parameters (such as blood pressure) and endogenous 
substances (such as plasma proteins) to pathobiological features specific to individual 
tumours (such as mutations). For example, as an on-target clinical biomarker, hypertension 
(systolic blood pressure ≥140mmHg) in patients receiving VEGF inhibitors has been shown 
to be associated with longer progression free survival and overall survival168. Additionally, 
many studies have looked into circulating biomarkers169, among which high levels of IL-6, 
IL-8, hepatocyte growth factor and osteopontin were associated with shorter progression free 
survival in patients receiving pazopanib and sunitinib170,171 whereas high levels of lactate 
dehydrogenase were associated with better overall survival in those receiving temsirolimus 
but not interferon-α172.
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Genetic biomarkers are also beginning to be studied for associations with treatment outcome 
in various metastatic settings173–175. For example, RECORD-3, a large randomized phase 2 
trial (n=471), demonstrated the better first-line efficacy of sunitinib (progression free 
survival of 10.7 months) over first-line everolimus (progression free survival of 7.9 
months)22. Interestingly, genomic biomarker analysis of patients enrolled in RECORD-3 
showed that BAP1 mutations were associated with 8.1 month progression free survival with 
first line sunitinib but 5.5 month with first-line everolimus — a significant difference. By 
contrast PBRM1 mutations showed no such association20, which is consistent with a VEGF 
inhibitor outlier study173 and warrants further validation. That BAP1 mutations were 
associated with inferior outcomes on everolimus20 is surprising given their reported higher 
mTORC1 activity than PBMR1 mutant tumours70. Furthermore, patients with KDM5C 
mutations were associated with a much longer first-line progression-free survival with 
sunitinib (20.6 months) than everolimus (9.8 months)20. As mutual exclusivity was detected 
between mutations of BAP1 and PBRM1 or KDM5C20, molecular subgrouping of 
metastatic ccRCC based on these three genes could be of clinical value in the future. In 
addition, case-based mTOR inhibitor outlier studies recognized activation mutations of 
MTOR and bi-allelic inactivation of TSC1 or TSC2 as potential biomarkers for long-term 
responders69,73,75,76.
Managing high-risk patients
A significant number (~30%) of patients with non-metastatic disease (based on clinical and 
pathological evaluation at the initial diagnosis) have occult metastases that will eventually 
become clinically evident. How to identify and better manage these high-risk patients 
presents a major challenge for operating urologists. As we begin to appreciate the impact 
that prevalent RCC mutations (in PBRM1, SETD2, BAP1, KDM5C, PTEN, and TP53) have 
on clinical outcomes, incorporating specific mutational information into prognostic 
nomograms will become increasingly useful. For example, transcription signatures such as 
ClearCode3486, and other biomarkers in the blood and urine, might be incorporated into 
validated predictive biomarkers for RCC recurrence after surgery. Similarly, predicting 
treatment response to systemic therapy might be plausible and will reduce cost and improve 
RCC cancer patient care. Our improving ability to identify high-risk patients with RCC and 
formulate personalized treatment and follow-up plans based on multi-omics holds the 
promise to quickly reduce the incidence of patients developing overt metastatic disease and 
render long-term survival.
Emerging therapies and changes to treatment
Several promising new drugs with novel mechanisms of action are in various stages of 
clinical trials. For immunotherapeutics, ipilimumab, an anti-CTLA-4 antibody, in 
combination with nivolumab has shown remarkable response rate of ~40% in the Checkmate 
016 trial176. Additionally, the efficacy of autologous dendritic cell-based immunotherapy, 
which consists of expanding patient’s own dendritic cells in vitro followed by the 
introduction of tumour RNA before re-infusion back to the patient, in combination with 
sunitinib has been examined and showed early promise177.
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In the realm of targeted therapeutics, inhibitors specifically targeting HIF-2 have been 
developed178,179. As kidney cancer is characterized by aberrant glycolysis (with aberrant 
glutamine and tryptophan metabolism65,180,181), it is of interest to learn if the glutaminase 
inhibitor CB-839182 and the indolemaine-2,3-dioxygenase inhibitor INCB024360183 could 
yield additional clinical benefits when added to existing therapies. Finally, as many of these 
novel therapeutic agents act on modulating the anti-cancer response in patients, further 
understanding of the intricate relationship between individual an kidney cancer cell and its 
respective immune microenvironment would be critical for the future success in designing 
combination treatment to improve survival87,184–187.
Given the increasing understanding of tumour biology and the increasing number of 
treatment options, how treatments are selected in the future will undoubtedly change (FIG. 
8). As well as those already discussed, potential measures of high values personalized 
vaccination188, targeted radiotherapy to enhance anti-tumour immune response189 and 
selective cytoreductive nephrectomy in patients who were initially inoperable but later 
showed marked shrinkage of tumours after systemic treatments. Additionally, neoadjuvant 
or adjuvant190 immunotherapy or targeted therapy could become integrated into the current 
treatment algorithms.
Preventing and overcoming drug resistance
Model systems and clinical experience have shown that inhibiting RCC activity with 
multiple drugs specific to different targets is superior to single-agent approaches23,191,192. 
However, such approaches tend to produce more toxicities — on and off-target. For 
example, the combination of sunitinib and everolimus in treating metastatic RCC subjected 
patients to severe toxicity193. Nevertheless, bevacizumab, a more tolerable VEGF pathway 
inhibitor than sunitinib, plus everolimus is well tolerated and has been shown to be 
efficacious in treating nccRCC with papillary features194. The success of polypharmacy 
relies on efficient and correct targeting of both primary and secondary (bypass) 
pathways69,195. In ccRCC, VEGF is the primary pathway due to the universal VHL loss; 
secondary targets can include mTORC1, MET and IL-8 but not EGFR or PI3K pathways 
when one takes into consideration of available clinical158,159,169,196,197 and preclinical 
studies92,198–200.
Given the availability of targeted therapies (FIG. 7), immediate challenge is to design the 
most effective and specific regimen through combining or sequencing drugs to prevent 
resistance in individual patients201. Interestingly, a recent study in melanoma patients who 
relapsed after the initial treatment response on PD-1 blockade revealed invaluable insights 
on how tumour cells might develop resistance to immunotherapies, including defects in 
interferon-receptor signalling and in antigen presentation 202. As immune checkpoint 
inhibitors functions independently of specific oncogenic pathways and incur distinct 
resistance mechanisms202, the combination of these drugs with targeted therapies is of great 
clinical interests203 and theoretically can prevent the emergence of escape mechanisms from 
either agent.
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Figure 1. Distinct subtypes of RCC
Approximately 75% of renal cell carcinomas (RCCs) are a | clear cell RCC (ccRCC). b | 
Papillary RCCs make up ~15% of all kidney cancers and are divided into two types based on 
staining features: b | type 1 (basophilic) and c | type 2 (eosinophilic). d | Chromophobe 
RCCs make up ~5% of kidney tumours. Other minor subtypes include e | MiT family 
translocation RCCs and f | collecting duct RCCs. Additional minor subtypes include 
medullary RCC, clear cell papillary RCC, acquired cystic disease-associated RCC, 
tubulocystic RCC, mucinous tubular and spindle RCC, succinate dehydrogenase-deficient 
RCC, hereditary leiomyomatosis, renal cell carcinoma-associated RCC and oncocytoma. 
Tumours not fitting into any of these categories are designated unclassified RCC. Scale bar = 
200 μm.
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Figure 2. Globalkidney cancer incidence
Estimated age-standardized rates (ASRs) of incidence for both sexes (per 100,000 persons) 
in 2012. Rates are generally higher in developed countries, with the highest incidence the 
Czech Republic (reasons unknown). Data from GLOBOCAN database; http://
globocan.iarc.fr.
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Figure 3. VHL inactivation in ccRCC and its implication in targeted therapy
Loss of VHL is the most frequent genetic feature of clear cell renal cell carcinoma (ccRCC). 
Its loss relieves the cell of negative regulation of the hypoxia inducible factors (HIFs), which 
results in increase HIF target gene expression and ensuing changes in cellular metabolism 
and signalling that enhances cell survival. For example, increased vascular endothelial 
growth factor (VEGF) expression increases angiogenesis in concert with increased 
signalling from growth factor receptors in endothelial cells in the tumour microenvironment 
(including fibroblast growth factor (FGF) and hepatocyte growth factor (HGF)). 
Collectively, these changes provide the targets for therapeutic agents to impede tumour 
growth, as indicated. FGFR, FGF receptor VEGFR, VEGF; TSC, tuberous sclerosis 
complex; PI3K, phosphatidylinositol 4,5-bisphosphate 3-kinase; AKT, RAC-α serine/
threonine-protein kinase; Rheb, GTP-binding protein Rheb; mTORC1, mTOR complex 1; 
mTORC2, mTOR complex 2; S6K1, ribosomal protein S6 kinase; 4EBP1, eukaryotic 
translation initiation factor 4E-binding protein 1; HRE, HIF response element; MET, 
hepatocyte growth factor receptor.
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Figure 4. Cancer evolution and tumour heterogeneity in ccRCC
Although VHL mutation and 3p loss of heterozygosity are early events that are evident in all 
clear cell renal cell carcinoma (ccRCC) cells regardless of the region of the tumour sampled, 
common driver mutations (for example, SETD2, MTOR and KDM5C mutations) are present 
heterogeneously — suggestive of subclonal evolution of the tumour. a | Cancer subclones 
originate from the most recent common ancestor cell (MRCA) in which a normal cell 
acquires all functional capacities to become cancer cell. b | Genomic heterogeneity can result 
from the sequential, parallel accumulation of mutations, contributing to the heterogeneity 
and the evolution of ccRCC. In this example, ‘R’ represents the genomic characteristics of 
the primary tumour and ‘M’ represents the genomic characteristics of the metastatic sites, 
numbered accordingly. The major genetic lesions acquired after VHL mutation feature in 
different samples and are indicated on the branches. c | However, some evidence suggests 
that tumours can converge by way of parallel evolution. Here, a hypothetical beaded river 
model depicts the sequential convergence of SETD2 and KDM5C mutations through 
different spatiotemporally distinct genetic events.
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Figure 5. Stages of kidney cancer and recommended treatments
Staging renal cell carcinoma (RCC) is based on size, position and lymph node 
involvement15. For example, a stage I or II tumour is enclosed wholly in the kidney. Stage 
III tumours can extend into major veins or adrenal glands within Gerota’s fascia (the layer of 
connective tissue encapsulating the kidneys and adrenal glands) or can involve one regional 
lymph node involvement. Stage IV tumours can invade beyond Gerota’s fascia and/or have 
distant metastases. *Until the introduction of newer targeted therapies beginning in 2005, the 
5-year survival of stage IV RCC was <10%. Treatment is largely guided by stage15,24. For 
example, those with stage I RCC who are fit for surgery are recommended partial 
nephrectomy. However, radical nephrectomy is also an option; for elderly patients or those 
who cannot undergo surgery owing to comorbidities, active surveillance or ablative therapies 
are recommended. In patients with stage III RCC, radical nephrectomy is recommended 
with lymph node dissection in those with clinical enlarged lymph nodes, but systemic 
therapies might be the only available option for those with extensive disease and poor 
performance status.
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Figure 6. Indications for radical nephrectomy
a | Radical nephrectomy could be considered in cases with multiple small renal tumours 
(circled). b | Conversely, radical nephrectomy and contextual excision of neoplastic 
thrombus into renal vein or cava vein tumour thrombus is the gold standard treatment for 
patients with venous involvement.
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Figure 7. Therapeutic evolution and survival outcome of metastatic ccRCC through the four 
different eras
a | Prior to 2004, two drugs were available to treat RCC (with a median survival of ~15 
months). This so-called dark age of treatments was followed by the modern age (2005–
2014), which saw seven additional regimens gain approval (increasing median survival to 
~30 months). Currently, the golden age has already witnessed the introduction of three 
drugs, with more anticipated over the next decade. b | These advances promise to be 
translated to a significant number of patients (~50%) achieving durable remissions under 
active surveillance by 2025 with a median survival of ~5 years. The ultimate goal is the 
future diamond age of drug approvals is >80% of patients with metastatic ccRCC long-term 
survival. Dashed lines represent predicted survival.
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Figure 8. Treatment algorithms for renal cell carcinoma
Given the advances in renal cell carcinoma (RCC) research, how patients are treated — 
based on their individual tumour characteristics — will likely change in the future.
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Table 3
Nephrometry scoring systems to predict partial nephrectomy complexity and outcomes.
Nephrometry system Parameters included Outcomes prediction External validation











Benign or malignant tumour
Tumour grade
Yes













Centrality Index 135 Tumour radius












Zonal NePhRo scoring system 137 Nearness
Physical zone
Tumour radius
Organization of the tumour
Perioperative complications No
Arterial Based Complexity Scoring 
System 138
Size of the renal arterial branches needing to 
be dissected or transected to achieve 




UCS, upper collecting system.
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Table 4
Selected adverse events and quality of life of the approved agents
Drug Adverse events Improvement inquality of life? Reference
Axitinib Hypertension, diarrhoea, hypothyroidism and hand–foot syndrome Yes versus sorafenib 157
Bevacizumab Proteinuria, hypertension and bleeding Not reported 160
Cabozantinib Diarrhoea, hand–foot syndrome, hypertension, nausea and 
hypothyroidism
Not reported
Everolimus Stomatitis, hypercholesterolaemia, hyperglycaemia and pneumonitis No versus placebo 209
Nivolumab Colitis, pneumonitis and endocrinopathies Yes versus everolimus 165
Pazopanib Diarrhoea, hypertension, liver function test abnormalities and hand–
foot syndrome
No versus placebo, Yes versus 
sunitinib
156
Sorafenib Hypertension, diarrhea, hand–foot syndrome and rash Yes versus placebo 154
Sunitinib Diarrhoea, hand–foot syndrome, mucositis and hypertension Yes versus IFN 155
Temsirolimus Stomatitis, hyperglycaemia, hypercholesterolaemia and oedema Yes versus IFN 210
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